Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 7 de 7
Filtre
Ajouter des filtres








Gamme d'année
1.
Indian J Dermatol Venereol Leprol ; 2009 Mar-Apr; 75(2): 189-90
Article Dans Anglais | IMSEAR | ID: sea-52784
3.
Indian J Dermatol Venereol Leprol ; 2007 Mar-Apr; 73(2): 109-11
Article Dans Anglais | IMSEAR | ID: sea-52253

Résumé

Aleukemic leukemia cutis has always been a dermatological curiosity. It is a rare condition characterized by the infiltration of skin by leukemic cells before their appearance in the peripheral blood or bone marrow. A 20 year old man had presented with nodular swelling on the scalp of 6 months duration along with cervical lymphadenopathy. Biopsy and immunohistochemistry revealed myeloid sarcoma. The initial presentation was aleukemic and repeated peripheral blood counts and marrow examinations were normal. However, the outcome was fatal within 3 months of diagnosis of cutaneous lesions.


Sujets)
Adulte , Issue fatale , Humains , Leucémies/diagnostic , Mâle , Pronostic , Sarcome myéloïde/diagnostic , Terminologie comme sujet
4.
5.
Indian J Dermatol Venereol Leprol ; 2004 Mar-Apr; 70(2): 92-5
Article Dans Anglais | IMSEAR | ID: sea-52739

Résumé

BACKGROUND: Tazarotene is a new third generation topical acetylenic retinoid. The present study was conducted to evaluate the efficacy and safety of tazarotene gel (0.1%) in Indian patients of acne vulgaris. METHODS: The present study was a prospective, open, multicentric, phase III trial. The duration of study was 14 weeks, including a 12-week active treatment period, preceded by a 2-week washout phase. Patients applied 0.1% tazarotene gel as a thin film over the affected area once daily in the evening. The efficacy was evaluated by analyzing changes in the number of facial acne lesions and patient's and physicians' global assessment. The efficacy parameters were assessed at baseline, visits 2, 4, 8, and 12 weeks. Tolerability and safety was assessed by physical examination, laboratory parameters and evaluation of adverse events. RESULTS: A total of 126 patients in 6 centers completed the study. At the end of the 8th and 12th weeks, the mean number of inflammatory lesions reduced by 70.6% and 86.1%, non-inflammatory lesions by 81.5% and 92%, and total lesion count 75.6% and 88.8% respectively from baseline. Also, 90.7% and 93.6% of total study cases showed complete to moderate clearance of acne lesions according to physicians at the end of the 8th and 12th weeks. CONCLUSIONS: This study confirms the efficacy and safety of tazarotene gel (0.1%) in Indian patients of acne vulgaris.

6.
Indian J Dermatol Venereol Leprol ; 2003 Nov-Dec; 69(6): 396-400
Article Dans Anglais | IMSEAR | ID: sea-53163

Résumé

AIM OF STUDY: Tacrolimus, a topical immunomodulator, has been introduced as a new treatment for moderate to severe atopic dermatitis. The present study was conducted to evaluate the efficacy, safety and tolerability of Tacrolimus ointment in patients of atopic dermatitis in an Indian setting. METHODS: The present study was a prospective, open, multicentric, Phase III trial.The duration of study was 5 weeks, including a 3-week active treatment period, preceded by a 1-week washout phase and followed by a 1-week follow-up phase. Patients diagnosed to be suffering from moderate to severe atopic dermatitis as per the Rajka and Langeland criteria were treated with Tacrolimus ointment 0.03% twice daily. Efficacy was assessed by modified Eczema Area Sensitivity Index (mEASI) score, patient's and physician's global assessment. Tolerability and safety was assessed by physical examination, laboratory parameters and evaluation of adverse events. RESULTS: There was a statistically significant decrease in the modified Eczema Area Sensitivity Index (mEASI) score (P< 0.05). Patient's and Physician's global evaluation of treatment was complete resolution to very good improvement in most of the patients. The laboratory values were within normal limits. The drug was well tolerated. CONCLUSIONS: This study confirms the efficacy and safety of Tacrolimus ointment 0.03% in Indian patients of moderate to severe atopic dermatitis.

7.
Indian J Dermatol Venereol Leprol ; 2001 Mar-Apr; 67(2): 89-90
Article Dans Anglais | IMSEAR | ID: sea-51972

Résumé

Appendageal tumours localized to the head, face and neck region continue to fascinate and confuse the dermatologists. We report a case of multiple apocrine hidrocystomas on the face of a 35 year-old woman. Good cosmetic result was obtained with excision followed by cauterization.

SÉLECTION CITATIONS
Détails de la recherche